We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa
Read MoreHide Full Article
BioLineRx Ltd announced encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, evaluating its lead pipeline candidate, BL-8040 (a CXCR4 antagonist), for treatment of patients with pancreatic cancer.
Shares of BioLineRx have outperformed the industry in a year’s time. The stock has rallied 15.2%, better than the industry’s 10.4% increase.
The monotherapy portion of this open-label, multicenter, single-arm COMBAT study is designed to evaluate multiple pharmacodynamic parameters of BL-8040 in this difficult-to-treat patient’s population. Partial data from the study showed that BL-8040 as a monotherapy is safe and well- tolerated in patients with the given indication. Additionally, results showed an increase in the number of T Cells, known to attack the tumor cancer cells in patients with metastatic pancreatic cancer after only five days of monotherapy with BL-8040.
The company said that outcomes from the trial will be presented on Jan 19, 2018 at ASCO 2018 (American Society of Clinical Oncology) Gastrointestinal Cancers Symposium in San Francisco.
Notably, BL-8040 is also being evaluated in combination with Merck’s (MRK - Free Report) anti-PD-1 therapy, Keytruda, under the COMBAT study for treatment of patients with pancreatic cancer. Notably, the program is conducted by BioLineRx under a collaboration signed with Merck in early 2016.
Apart from Merck, BioLineRx has a collaboration agreement with Roche Holding’s (RHHBY - Free Report) Genentech for the evaluation of BL-8040 in combination with the latter’s Tecentriq (atezolizumab) for multiple solid tumor indications.
We remind investors that in October 2017, BioLineRx and Roche had initiated a phase Ib/II study to evaluate BL-8040 in combination with Roche’s Tecentriq for treating patients with gastric cancer.
Per the data provided by the American Cancer Society, approximately 55,440 patients will be diagnosed with pancreatic cancer in the United States in 2018. The disease in various types is the seventh most common cause of cancer deaths, accounting for about 3% of all cancers. This further indicates huge market potential for the combination therapy.
Exelixis’ earnings per share estimates have been revised upward from 72 cents to 73 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in each of the trailing four quarters with an average beat of 572.92%. Share price of the company has soared 52.5% in a year’s time.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa
BioLineRx Ltd announced encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, evaluating its lead pipeline candidate, BL-8040 (a CXCR4 antagonist), for treatment of patients with pancreatic cancer.
Shares of BioLineRx have outperformed the industry in a year’s time. The stock has rallied 15.2%, better than the industry’s 10.4% increase.
The monotherapy portion of this open-label, multicenter, single-arm COMBAT study is designed to evaluate multiple pharmacodynamic parameters of BL-8040 in this difficult-to-treat patient’s population. Partial data from the study showed that BL-8040 as a monotherapy is safe and well- tolerated in patients with the given indication. Additionally, results showed an increase in the number of T Cells, known to attack the tumor cancer cells in patients with metastatic pancreatic cancer after only five days of monotherapy with BL-8040.
The company said that outcomes from the trial will be presented on Jan 19, 2018 at ASCO 2018 (American Society of Clinical Oncology) Gastrointestinal Cancers Symposium in San Francisco.
Notably, BL-8040 is also being evaluated in combination with Merck’s (MRK - Free Report) anti-PD-1 therapy, Keytruda, under the COMBAT study for treatment of patients with pancreatic cancer. Notably, the program is conducted by BioLineRx under a collaboration signed with Merck in early 2016.
Apart from Merck, BioLineRx has a collaboration agreement with Roche Holding’s (RHHBY - Free Report) Genentech for the evaluation of BL-8040 in combination with the latter’s Tecentriq (atezolizumab) for multiple solid tumor indications.
We remind investors that in October 2017, BioLineRx and Roche had initiated a phase Ib/II study to evaluate BL-8040 in combination with Roche’s Tecentriq for treating patients with gastric cancer.
Per the data provided by the American Cancer Society, approximately 55,440 patients will be diagnosed with pancreatic cancer in the United States in 2018. The disease in various types is the seventh most common cause of cancer deaths, accounting for about 3% of all cancers. This further indicates huge market potential for the combination therapy.
BioLineRx Ltd. Price
BioLineRx Ltd. Price | BioLineRx Ltd. Quote
Zacks Rank & Key Pick
BioLineRx carries a Zacks Rank #4 (Sell).
A better-ranked stock in the health care sector is Exelixis, Inc. (EXEL - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Exelixis’ earnings per share estimates have been revised upward from 72 cents to 73 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in each of the trailing four quarters with an average beat of 572.92%. Share price of the company has soared 52.5% in a year’s time.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2018 today >>